Herceptin News and Research

RSS

Trastuzumab drug increases risk of heart problems in elderly breast cancer patients

The first study to investigate the effect of the breast cancer drug trastuzumab (Herceptin) on heart and vascular function in elderly patients has found that it increases the risk of heart problems, particularly in women with a history of heart disease, diabetes or both.

10 Aug 2011

Novel studies explore new targets to prevent spread of breast cancer

Research into new methods to prevent and slow metastatic breast cancer will be presented this week at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program.

5 Aug 2011

Better targeting of pharmaceuticals to patient's genetic profile could save around $110B annually

Genetic testing made possible by the mapping of the human genome can help the US cut costs and create jobs while at the same time improving survival rates for such diseases as cancer, HIV, and heart disease.

25 Jul 2011

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint.

15 Jul 2011

RXi expands intellectual property portfolio with additional NeuVax patents

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax.

14 Jul 2011

FDA issues draft guidance to promote development of targeted medicines, diagnostics

The U.S. Food and Drug Administration today issued a new draft guidance to facilitate the development and review of companion diagnostics – tests used to help health care professionals determine whether a patient with a particular disease or condition should receive a particular drug therapy or how much of the drug to give.

13 Jul 2011

Nevada District Court rules in favor of PDL over Genentech, Roche lawsuit

PDL BioPharma, Inc. (PDL) announced a favorable ruling today, specifically, that on July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and F. Hoffmann LaRoche, Ltd. in PDL's lawsuit related to the 2003 settlement agreement with Genentech.

11 Jul 2011

Combination therapy shows promise against HER2-positive metastatic breast cancer

Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology.

11 Jul 2011

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.

27 Jun 2011

Ventana Medical receives FDA approval for new breast cancer genetic test

The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin, a commonly used breast cancer treatment.

15 Jun 2011

PDL revises revenue guidance for second quarter 2011 to $122M

PDL BioPharma, Inc. (PDL) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase.

9 Jun 2011

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, presented Phase 2 efficacy results for NeuVax in combination with trastuzumab at the American Society of Clinical Oncology (ASCO) annual meeting.

8 Jun 2011

U of A researchers try to combat heart disease in cancer patients

Researchers in the Faculty of Medicine & Dentistry are trying to reverse a devastating trend: cancer survivors developing cardiovascular disease, one of the top two killers in Canada.

4 Jun 2011

Starving breast cancer cells of hedgehog significantly slows tumour growth and spread

While it is already known that breast cancer cells create the conditions for their own survival by communicating their needs to the healthy cells that surround them, Australian researchers have identified a new way of turning off that cellular cross talk.

4 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

Herceptin News and Research

Trastuzumab drug increases risk of heart problems in elderly breast cancer patients

Novel studies explore new targets to prevent spread of breast cancer

Better targeting of pharmaceuticals to patient's genetic profile could save around $110B annually

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

RXi expands intellectual property portfolio with additional NeuVax patents

FDA issues draft guidance to promote development of targeted medicines, diagnostics

Nevada District Court rules in favor of PDL over Genentech, Roche lawsuit

Combination therapy shows promise against HER2-positive metastatic breast cancer

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

Ventana Medical receives FDA approval for new breast cancer genetic test

PDL revises revenue guidance for second quarter 2011 to $122M

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

U of A researchers try to combat heart disease in cancer patients

Starving breast cancer cells of hedgehog significantly slows tumour growth and spread

Researcher to evaluate new approach for treatment of triple-negative breast cancer

PTEN does not reduce effectiveness of breast cancer drug, Herceptin: Study

Two genes linked to worst cases of esophageal cancer

Study: 80% of U.S. physicians use Herceptin for HER2-positive metastatic gastric cancer treatment

New avenue for treating breast cancer

Rethink praises Ontario's decision to provide breast cancer patients with access to Herceptin

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News